Sernova Corp. (SEOVF)
USD 0.13
(0.15%)
USD 0.13
(0.15%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 22.1 Million CAD | -57.88% |
| 2022 | 52.48 Million CAD | 76.0% |
| 2021 | 29.82 Million CAD | 420.83% |
| 2020 | 5.72 Million CAD | 2.82% |
| 2019 | 5.56 Million CAD | 54.46% |
| 2018 | 3.6 Million CAD | -20.79% |
| 2017 | 4.55 Million CAD | -26.89% |
| 2016 | 6.22 Million CAD | 97.42% |
| 2015 | 3.15 Million CAD | -21.58% |
| 2014 | 4.02 Million CAD | -35.6% |
| 2013 | 6.24 Million CAD | 0.66% |
| 2012 | 6.2 Million CAD | 55.95% |
| 2011 | 3.97 Million CAD | -1.42% |
| 2010 | 4.03 Million CAD | -10.19% |
| 2009 | 4.49 Million CAD | -12.77% |
| 2008 | 5.14 Million CAD | -28.8% |
| 2007 | 7.23 Million CAD | 15.75% |
| 2006 | 6.24 Million CAD | 1170.84% |
| 2005 | 491.66 Thousand CAD | 45.9% |
| 2004 | 336.98 Thousand CAD | -16.01% |
| 2003 | 401.24 Thousand CAD | -30.21% |
| 2002 | 574.92 Thousand CAD | -67.77% |
| 2001 | 1.78 Million CAD | -25.8% |
| 2000 | 2.4 Million CAD | 443.05% |
| 1999 | 442.68 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 7.45 Million CAD | -36.63% |
| 2024 Q1 | 18.57 Million CAD | -15.99% |
| 2024 Q2 | 11.76 Million CAD | -36.65% |
| 2023 Q4 | 22.1 Million CAD | -33.42% |
| 2023 Q1 | 46.96 Million CAD | -10.53% |
| 2023 Q3 | 33.2 Million CAD | -12.71% |
| 2023 Q2 | 38.03 Million CAD | -19.0% |
| 2023 FY | 22.1 Million CAD | -57.88% |
| 2022 Q4 | 52.48 Million CAD | 17.72% |
| 2022 Q1 | 29.5 Million CAD | -1.05% |
| 2022 FY | 52.48 Million CAD | 76.0% |
| 2022 Q2 | 26.71 Million CAD | -9.45% |
| 2022 Q3 | 44.58 Million CAD | 66.87% |
| 2021 Q4 | 29.82 Million CAD | -4.79% |
| 2021 Q2 | 32.5 Million CAD | 204.64% |
| 2021 FY | 29.82 Million CAD | 420.83% |
| 2021 Q1 | 10.67 Million CAD | 86.37% |
| 2021 Q3 | 31.32 Million CAD | -3.65% |
| 2020 Q2 | 3.18 Million CAD | -24.5% |
| 2020 FY | 5.72 Million CAD | 2.82% |
| 2020 Q1 | 4.21 Million CAD | -24.28% |
| 2020 Q3 | 2.9 Million CAD | -8.65% |
| 2020 Q4 | 5.72 Million CAD | 96.88% |
| 2019 FY | 5.56 Million CAD | 54.46% |
| 2019 Q4 | 5.56 Million CAD | 173.96% |
| 2019 Q3 | 2.03 Million CAD | -26.53% |
| 2019 Q2 | 2.76 Million CAD | -10.74% |
| 2019 Q1 | 3.09 Million CAD | -14.02% |
| 2018 Q1 | 3.76 Million CAD | -17.29% |
| 2018 Q3 | 4.51 Million CAD | 55.89% |
| 2018 Q4 | 3.6 Million CAD | -20.21% |
| 2018 FY | 3.6 Million CAD | -20.79% |
| 2018 Q2 | 2.89 Million CAD | -23.01% |
| 2017 Q2 | 5.82 Million CAD | -1.95% |
| 2017 Q4 | 4.55 Million CAD | -18.39% |
| 2017 FY | 4.55 Million CAD | -26.89% |
| 2017 Q1 | 5.93 Million CAD | -4.6% |
| 2017 Q3 | 5.57 Million CAD | -4.22% |
| 2016 Q2 | 3.08 Million CAD | -17.72% |
| 2016 FY | 6.22 Million CAD | 97.42% |
| 2016 Q1 | 3.75 Million CAD | 18.98% |
| 2016 Q4 | 6.22 Million CAD | -3.76% |
| 2016 Q3 | 6.46 Million CAD | 109.55% |
| 2015 Q3 | 3.81 Million CAD | 38.31% |
| 2015 Q1 | 3.31 Million CAD | -17.44% |
| 2015 Q2 | 2.75 Million CAD | -16.93% |
| 2015 FY | 3.15 Million CAD | -21.58% |
| 2015 Q4 | 3.15 Million CAD | -17.33% |
| 2014 Q2 | 5.13 Million CAD | -8.94% |
| 2014 FY | 4.02 Million CAD | -35.6% |
| 2014 Q3 | 4.66 Million CAD | -9.09% |
| 2014 Q4 | 4.02 Million CAD | -13.82% |
| 2014 Q1 | 5.63 Million CAD | -9.73% |
| 2013 Q4 | 6.24 Million CAD | -6.39% |
| 2013 Q3 | 6.66 Million CAD | -5.98% |
| 2013 Q2 | 7.09 Million CAD | -8.1% |
| 2013 Q1 | 7.71 Million CAD | 24.45% |
| 2013 FY | 6.24 Million CAD | 0.66% |
| 2012 FY | 6.2 Million CAD | 55.95% |
| 2012 Q2 | 7.1 Million CAD | 109.88% |
| 2012 Q4 | 6.2 Million CAD | -8.64% |
| 2012 Q3 | 6.78 Million CAD | -4.39% |
| 2012 Q1 | 3.38 Million CAD | -14.93% |
| 2011 FY | 3.97 Million CAD | -1.42% |
| 2011 Q1 | 4.2 Million CAD | 4.19% |
| 2011 Q2 | 3.67 Million CAD | -12.63% |
| 2011 Q3 | 4.14 Million CAD | 12.77% |
| 2011 Q4 | 3.97 Million CAD | -3.96% |
| 2010 FY | 4.03 Million CAD | -10.19% |
| 2010 Q1 | 4.14 Million CAD | -7.83% |
| 2010 Q2 | 4.15 Million CAD | 0.39% |
| 2010 Q4 | 4.03 Million CAD | 3.07% |
| 2010 Q3 | 3.91 Million CAD | -5.82% |
| 2009 Q1 | 4.82 Million CAD | -6.24% |
| 2009 Q4 | 4.49 Million CAD | -0.28% |
| 2009 Q3 | 4.5 Million CAD | 0.56% |
| 2009 FY | 4.49 Million CAD | -12.77% |
| 2009 Q2 | 4.47 Million CAD | -7.22% |
| 2008 Q4 | 5.14 Million CAD | -7.16% |
| 2008 Q3 | 5.54 Million CAD | -8.96% |
| 2008 Q2 | 6.09 Million CAD | -8.39% |
| 2008 Q1 | 6.65 Million CAD | -8.05% |
| 2008 FY | 5.14 Million CAD | -28.8% |
| 2007 Q3 | 7.54 Million CAD | 14.78% |
| 2007 Q1 | 6.22 Million CAD | -0.32% |
| 2007 Q4 | 7.23 Million CAD | -4.15% |
| 2007 FY | 7.23 Million CAD | 15.75% |
| 2007 Q2 | 6.57 Million CAD | 5.54% |
| 2006 Q3 | 3.49 Million CAD | 464.68% |
| 2006 Q4 | 6.24 Million CAD | 78.94% |
| 2006 FY | 6.24 Million CAD | 1170.84% |
| 2006 Q1 | 444.39 Thousand CAD | -9.61% |
| 2006 Q2 | 618.36 Thousand CAD | 39.15% |
| 2005 Q1 | 244.81 Thousand CAD | -27.35% |
| 2005 Q2 | 145.65 Thousand CAD | -40.5% |
| 2005 FY | 491.66 Thousand CAD | 45.9% |
| 2005 Q3 | 537.52 Thousand CAD | 269.03% |
| 2005 Q4 | 491.66 Thousand CAD | -8.53% |
| 2004 Q4 | 336.98 Thousand CAD | -3.71% |
| 2004 Q2 | 434.43 Thousand CAD | 18.0% |
| 2004 FY | 336.98 Thousand CAD | -16.01% |
| 2004 Q1 | 368.15 Thousand CAD | -8.25% |
| 2004 Q3 | 349.97 Thousand CAD | -19.44% |
| 2003 Q4 | 401.24 Thousand CAD | -22.79% |
| 2003 Q1 | 788.05 Thousand CAD | 37.07% |
| 2003 Q3 | 519.67 Thousand CAD | -3.29% |
| 2003 FY | 401.24 Thousand CAD | -30.21% |
| 2003 Q2 | 537.36 Thousand CAD | -31.81% |
| 2002 Q2 | 739.49 Thousand CAD | -42.53% |
| 2002 Q3 | 440.4 Thousand CAD | -40.44% |
| 2002 Q4 | 574.92 Thousand CAD | 30.54% |
| 2002 Q1 | 1.28 Million CAD | 0.0% |
| 2002 FY | 574.92 Thousand CAD | -67.77% |
| 2001 FY | 1.78 Million CAD | -25.8% |
| 2000 FY | 2.4 Million CAD | 443.05% |
| 1999 FY | 442.68 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 52.7 Million USD | 58.052% |
| Skye Bioscience, Inc. | 11.94 Million USD | -85.143% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 83.022% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -3903.987% |
| Qrons Inc. | 420.00 USD | -5263427.381% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -51.829% |
| CSL Limited | 38.02 Billion USD | 99.942% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -109.464% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1028.942% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -6151.627% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 20.889% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -4500.248% |
| Rebus Holdings, Inc. | 5000.00 USD | -442036.3% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -956904.978% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -2768.616% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -3115.602% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 43.093% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -206.199% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -28853.054% |
| SQZ Biotechnologies Company | 107.18 Million USD | 79.375% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1443.738% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -30449.043% |
| Mesoblast Limited | 667.9 Million USD | 96.69% |
| Marizyme, Inc. | 22.01 Million USD | -0.417% |
| Genus plc | 1.02 Billion USD | 97.851% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1527.472% |
| Pharming Group N.V. | 462.85 Million USD | 95.224% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -567.272% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -4329.877% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -3425.808% |
| ContraFect Corporation | 20.67 Million USD | -6.905% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -5563.1% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -5684.444% |
| IMV Inc. | 31.33 Million USD | 29.447% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -433.205% |
| MultiCell Technologies, Inc. | 126.22 USD | -17514410.379% |
| ONE Bio Corp. | 70.08 Million USD | 68.457% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -2252.567% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 82.798% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -5020.708% |
| Q BioMed Inc. | 3.51 Million USD | -528.835% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 37.159% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -8361.064% |
| Biomind Labs Inc. | 73.81 Thousand USD | -29847.324% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 95.047% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1425.825% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 26.347% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -704.957% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -749.218% |
| GB Sciences, Inc. | 103.44 Thousand USD | -21271.218% |
| Alpha Cognition Inc. | 2.45 Million USD | -801.52% |
| HST Global, Inc. | 1526.00 USD | -1448577.261% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -2137.607% |
| Halberd Corporation | 10.13 Thousand USD | -218109.604% |
| Enzolytics Inc. | 361.7 Million USD | 93.888% |
| Agentix Corp. | 261.39 Thousand USD | -8357.342% |
| Resverlogix Corp. | 8.11 Million USD | -172.419% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -1077.222% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.513% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 53.656% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -3356.047% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -96940.582% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -147.027% |
| AVAX Technologies, Inc. | 7.37 Million USD | -199.666% |
| Zenith Capital Corp. | 7410.00 USD | -298237.584% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.347% |
| Ember Therapeutics, Inc. | 184.00 USD | -12014473.37% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -6769.609% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -8358.248% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -2282.3% |
| Kadimastem Ltd | 2.3 Million USD | -859.464% |
| Helix BioMedix, Inc. | 3.02 Million USD | -630.783% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -38620.032% |
| LadRx Corporation | 2.3 Million USD | -857.883% |
| Cell Source, Inc. | 195.17 Thousand USD | -11226.895% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -6151.627% |
| NovAccess Global Inc. | 62.24 Thousand USD | -35414.097% |
| Affymax, Inc. | 7.44 Million USD | -197.015% |
| Itoco Inc. | 1.4 Million USD | -1478.977% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -23010.504% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -20755.486% |
| Mobile Lads Corp. | 52.00 USD | -42513005.769% |
| CytoDyn Inc. | 11.13 Million USD | -98.517% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -15362.339% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -123539.905% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -5635.014% |
| SYBLEU INC | 330.46 Thousand USD | -6589.548% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -5299.518% |
| International Stem Cell Corporation | 5.39 Million USD | -310.145% |
| Bioxytran, Inc. | 137.63 Thousand USD | -15961.564% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -47.361% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -33.342% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -27883.31% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -2456.656% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -194.091% |
| Neutra Corp. | 2851.00 USD | -775305.647% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 31.782% |
| PureTech Health plc | 693.97 Million USD | 96.814% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -173.901% |
| IXICO plc | 15.84 Million USD | -39.529% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -166.926% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 78.604% |
| CSL Limited | 38.02 Billion USD | 99.942% |
| Cellectis S.A. | 333.99 Million USD | 93.381% |